药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
4-Methoxyamphetamine
Dexchlorpheniramine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Dexchlorpheniramine.
4-Methoxyamphetamine
Lorcainide
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Lorcainide.
4-Methoxyamphetamine
Bunaftine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Bunaftine.
4-Methoxyamphetamine
Nizofenone
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Nizofenone.
4-Methoxyamphetamine
Otilonium
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Otilonium.
4-Methoxyamphetamine
Sultopride
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Sultopride.
4-Methoxyamphetamine
Sitafloxacin
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Sitafloxacin.
4-Methoxyamphetamine
Oxatomide
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Oxatomide.
4-Methoxyamphetamine
Abexinostat
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Abexinostat.
4-Methoxyamphetamine
Mizolastine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Mizolastine.
4-Methoxyamphetamine
Ricolinostat
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Ricolinostat.
4-Methoxyamphetamine
Simendan
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Simendan.
4-Methoxyamphetamine
CUDC-101
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with CUDC-101.
4-Methoxyamphetamine
Gilteritinib
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Gilteritinib.
4-Methoxyamphetamine
Entinostat
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Entinostat.
4-Methoxyamphetamine
Mocetinostat
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Mocetinostat.
4-Methoxyamphetamine
Encorafenib
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Encorafenib.
4-Methoxyamphetamine
Amifampridine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Amifampridine.
4-Methoxyamphetamine
Delamanid
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Delamanid.
4-Methoxyamphetamine
Dexchlorpheniramine maleate
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Dexchlorpheniramine maleate.